Johnson & Johnson (JNJ)

Outperform Current rating · 4 reports

2026-04-15

Outperform Recap: Q1 2026

Op Sales +6.4% (Double-Digit ex-STELARA), FY26 Raised to $100.8B / $11.55 EPS, ICOTYDE and INLEXZO Off the Blocks — Maintaining Outperform, FV $190–220

2026-01-22

Outperform Recap: Q4 2025

$100B FY26 Guide, TREMFYA +65%, Daubert Special Master Largely Favorable — Maintaining Outperform, FV $190–220

2025-10-15

Outperform Recap: Q3 2025

Upgrading to Outperform: STELARA's Worst Quarter Is in the Books, IM Grows Through the Trough, MedTech Accelerates Across All Subsegments, and the DePuy Synthes Spin Structurally Re-Rates the Remaining Franchise

2025-07-17

Hold Recap: Q2 2025

Initiating Coverage at Hold: A Clean Beat-and-Raise Through STELARA's First-Year Cliff, MedTech Reaccelerates to +6.1%, but the Biosimilar Curve Is Still Steepening and Talc Stays Unresolved